Form 4: Axogen Director Sells Shares via Pre-Arranged Plan

Axogen Director William P. Burke sold 32,191 shares of common stock in early October 2025 through Rule 10b5-1 trading plans.

Summary

• William P. Burke, a Director of Axogen, Inc. (AXGN), reported multiple sales of common stock.
• A total of 32,191 shares were sold across four transactions on October 2, 2025, and October 3, 2025.
• The sales were executed at weighted average prices ranging from $18.0053 to $18.2062 per share.
• All reported sales were made pursuant to Rule 10b5-1(c) trading plans adopted on March 14, 2025.
• Transactions included both direct holdings and shares held indirectly through the Elizabeth J. Burke 2024 Irrevocable Trust, where Mr. Burke is a stakeholder and Trustee.
• Following these transactions, Mr. Burke's direct beneficial ownership stands at 2,293 shares, and indirect beneficial ownership through the Trust is 0 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be perceived negatively, these transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates they were scheduled in advance and not necessarily based on new, non-public information.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a standard disclosure of insider trading activity and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• Sales of 2,400 shares and 7,600 shares were made from the Elizabeth J. Burke 2024 Irrevocable Trust, of which William P. Burke is a stakeholder and a Trustee.

Stakeholder Impact

• Shareholders may observe the insider selling, which could be interpreted in various ways, though the existence of a 10b5-1 plan typically mitigates concerns about opportunistic selling.

Key Dates

Recommendation

The filing reports routine insider sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are generally not indicative of a significant change in the company's fundamental prospects or a lack of confidence from the insider, as they are scheduled in advance. Therefore, this specific filing alone does not warrant a change in investment recommendation, suggesting a 'hold' position for existing investors.

Keywords

Axogen, AXGN, Insider Trading, Form 4, Director Share Sale, William P. Burke, 10b5-1 Plan